ArticleFrontiers in immunology2021
S100A2 Is a Prognostic Biomarker Involved in Immune Infiltration and Predict Immunotherapy Response in Pancreatic Cancer.
Article in Frontiers in immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 2 syntheses or guidelines pooled it, 48 citations in OpenAlex.
- Global research trends and hotspots in prognostic prediction models for pancreatic cancer: a bibliometric analysis.Frontiers in oncology · 2025Pooled it
- Research advances and treatment perspectives of pancreatic adenosquamous carcinoma.Cellular oncology (Dordrecht, Netherlands) · 2023Pooled it
- Transcriptomic analysis of genes in bladder cancer patients with resistance to neoadjuvant chemoimmunotherapy.BMC cancer · 2026Article
- Interplay of RNA mFASEB bioAdvances · 2026Article
- E2F7 targets S100A2 to suppress CD8Journal of molecular medicine (Berlin, Germany) · 2026Article
- Neutrophil-Specific Biomarker S100A2 Mediates Diabetic Foot Ulcer Through IL-17 Signaling Pathway and Potential Therapeutics.Journal of inflammation research · 2026Article
- Role of S100 family proteins in colorectal cancer (CRC): an overview of their potential function as new biomarkers and therapeutic agents.Expert reviews in molecular medicine · 2025Review
- TRPV4 drives the progression of leiomyosarcoma by promoting ECM1 generation and co-activating the FAK/PI3K/AKT/GSK3β pathway.Cellular oncology (Dordrecht, Netherlands) · 2025Article
- S100A2 promotes clear cell renal cell carcinoma tumor metastasis through regulating GLUT2 expression.Cell death & disease · 2025Article
- KRT7 promotes pancreatic cancer metastasis by remodeling the extracellular matrix niche through FGF2-fibroblast crosstalk.Scientific reports · 2025Article
- Taurine Synthesis by 2-Aminoethanethiol Dioxygenase as a Vulnerable Metabolic Alteration in Pancreatic Cancer.Biomolecules & therapeutics · 2025Article
- An integrated approach for analyzing spatially resolved multi-omics datasets from the same tissue section.Frontiers in molecular biosciences · 2025Article
- S100A2 upregulates GLUT1 expression to promote glycolysis in the progression of nasopharyngeal carcinoma.Histology and histopathology · 2024Article
- S100A2 activation promotes interstitial fibrosis in kidneys by FoxO1-mediated epithelial-mesenchymal transition.Cell biology and toxicology · 2024Article
- Patient-derived organoids of pancreatic ductal adenocarcinoma for subtype determination and clinical outcome prediction.Journal of gastroenterology · 2024Article
- Single-cell and bulk RNA sequencing reveal heterogeneity and diagnostic markers in papillary thyroid carcinoma lymph-node metastasis.Journal of endocrinological investigation · 2024Article
- The S100 family is a prognostic biomarker and correlated with immune cell infiltration in pan-cancer.Discover oncology · 2024Article
- FAM53B promotes pancreatic ductal adenocarcinoma metastasis by regulating macrophage M2 polarization.World journal of gastrointestinal oncology · 2024Article
- Identifying the NEAT1/miR-26b-5p/S100A2 axis as a regulator in Parkinson's disease based on the ferroptosis-related genes.PloS one · 2024Article
- Multi-omics Analysis Identifies Hypoxia Subtypes and S100A2 as an Immunosuppressive Factor in Cervical Cancer.Reproductive sciences (Thousand Oaks, Calif.) · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pancreatic cancer (PC) is a highly fatal and aggressive disease with its incidence and mortality quite discouraging. It is of great significance to construct an effective prognostic signature of PC and find the novel biomarker for the optimization of the clinical decision-making. Due to the crucial role of immunity in tumor development, a prognostic model based on nine immune-related genes was constructed, which was proved to be effective in The Cancer Genome Atlas (TCGA) training set, TCGA testing set, TCGA entire set, GSE78229 set, and GSE62452 set. Furthermore, S100A2 (S100 Calcium Binding Protein A2) was identified as the gene occupying the most paramount position in risk model. Gene set enrichment analysis (GSEA), ESTIMATE and CIBERSORT algorithm revealed that S100A2 was closely associated with the immune status in PC microenvironment, mainly related to lower proportion of CD8+T cells and activated NK cells and higher proportion of M0 macrophages. Meanwhile, patients with high S100A2 expression might get more benefit from immunotherapy according to immunophenoscore algorithm. Afterwards, our independent cohort was also used to demonstrate S100A2 was an unfavorable marker of PC, as well as its remarkably positive correlation with the expression of PD-L1. In conclusion, our results demonstrate S100A2 might be responsible for the preservation of immune-suppressive status in PC microenvironment, which was identified with significant potentiality in predicting prognosis and immunotherapy response in PC patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.